Lurasidone-d8

Lurasidone-d8 is deuterium labeled Lurasidone. Lurasidone (SM-13496) is an antagonist of both dopamine D2 and 5-HT7 with IC50s of 1.68 and 0.495 nM, respectively. Lurasidone (SM-13496) is also a partial agonist of 5-HT1A receptor with an IC50 of 6.75 nM.

Product Specifications

CAS Number

[1132654-54-6]

Product Name Alternative

SM-13496-d8

UNSPSC

12352005

Hazard Statement

H302+H312+H332-H315-H317-H319-H361

Target

5-HT Receptor; Dopamine Receptor

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Solubility

10 mM in DMSO

Smiles

O=C1[C@@]2([H])[C@](C(N1C[C@H]3[C@@H](CCCC3)CN4C([2H])([2H])C([2H])([2H])N(C5=NSC6=CC=CC=C56)C([2H])([2H])C4([2H])[2H])=O)([H])[C@H]7C[C@@H]2CC7

Molecular Formula

C28H28D8N4O2S

Molecular Weight

500.73

Precautions

P261-P264-P270-P271-P272-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P405-P501

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Ishibashi T, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010 Jul;334 (1) :171-81.|[3]Sakine Atila Karaca, et al. Development of a validated high-performance liquid chromatographic method for the determination of Lurasidone in pharmaceuticals. Marmara Pharm J. 2017;21 (4) : 931-937.